EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis

Clara Ribera, Ariadna Padullés, Fe Tubau, Luisa Corral, Maria Nuñez Garate, Carmen Cabellos, Alexandre Vilalta, Jordi Càmara iD, Sara Cobo-Sacristán, Gabriela Abelenda-Alonso, Fabio Di Paolo, Evelyn Shaw iD und 1 weitere

JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)

DOI: 10.1093/jacamr/dlag092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 02.06.2026. Verfasst von Clara Ribera und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bacterial ventriculitis associated with CSF shunts or drains is a life-threatening infection often caused by MDR pathogens such as Stenotrophomonas maltophilia. Cefiderocol, an IV siderophore cephalosporin approved for drug-resistant Gram-negative infections, lacks extensive clinical data supporting its use in CNS infections.

Objectives

We describe a case of S. maltophilia ventriculitis successfully treated with cefiderocol monotherapy at a standard dose of 2 g IV every 8 h. Data on cefiderocol CSF drug penetration are reported.

Methods

Cefiderocol trough plasma and CSF concentrations (Cmin) were determined at steady-state conditions, and S. maltophilia susceptibility testing was determined using Etest and disc diffusion.

Results

Therapeutic drug monitoring showed sustained CSF cefiderocol concentrations. CSF cefiderocol Cmin remained 116.0- and 131.8-fold above the isolate’s MIC throughout the dosing interval, with plasma-to-CSF penetration ratios of 16.6%–25.7%. Patient’s clinical cure was achieved after 26 days of therapy without adverse events or relapse at 1 year of follow-up.

Conclusions

Our data show that cefiderocol at a standard dose of 2 g IV every 8 h achieved sustained therapeutic concentrations in the CSF. Cefiderocol monotherapy may be an option for CNS infections with MDR Gram-negative bacteria with low MICs such as S. maltophilia.

Autor:innen und Institutionen

  • Pharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • University of Barcelona, Faculty of Pharmacy, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Clinical Microbiology, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Research Network for Respiratory Diseases (CIBERES-CB06/06/0037), Instituto de Salud Carlos III, Madrid, Spain.
  • Intensive Care Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

ORCID-Profile: Jordi Càmara, Evelyn Shaw, Mireia Puig-Asensio

Zitieren

APA

Ribera, C., Padullés, A., Tubau, F., Corral, L., Nuñez Garate, M., Cabellos, C., Vilalta, A., Càmara, J., Cobo-Sacristán, S., Abelenda-Alonso, G., Di Paolo, F., Shaw, E., & Puig-Asensio, M. (2026). Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag092

Vancouver

Ribera C, Padullés A, Tubau F, Corral L, Nuñez Garate M, Cabellos C, et al. Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag092

BibTeX
@article{Ribera2026,
  author = {Ribera, Clara and Padullés, Ariadna and Tubau, Fe and Corral, Luisa and Nuñez Garate, Maria and Cabellos, Carmen and Vilalta, Alexandre and Càmara, Jordi and Cobo-Sacristán, Sara and Abelenda-Alonso, Gabriela and Di Paolo, Fabio and Shaw, Evelyn and Puig-Asensio, Mireia},
  title = {Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.1093/jacamr/dlag092}
}
Kostenlos starten →